

François Curtin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4583445/publications.pdf>

Version: 2024-02-01

37
papers

3,348
citations

331670

21
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

3135
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Meta-analyses involving cross-over trials: methodological issues. <i>International Journal of Epidemiology</i> , 2002, 31, 140-149. | 1.9 | 1,999 |
| 2 | Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. <i>Statistics in Medicine</i> , 2002, 21, 2131-2144. | 1.6 | 192 |
| 3 | Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. <i>Statistics in Medicine</i> , 2002, 21, 2145-2159. | 1.6 | 113 |
| 4 | Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. <i>Statistics in Medicine</i> , 2002, 21, 2161-2173. | 1.6 | 112 |
| 5 | MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNBAC1 in multiple sclerosis treatment. <i>Journal of Neuroimmunology</i> , 2016, 291, 29-38. | 2.3 | 70 |
| 6 | GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis-Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study. <i>Clinical Therapeutics</i> , 2012, 34, 2268-2278. | 2.5 | 68 |
| 7 | Preclinical and early clinical development of GNBAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. <i>MAbs</i> , 2015, 7, 265-275. | 5.2 | 68 |
| 8 | The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity. <i>PLoS ONE</i> , 2013, 8, e53623. | 2.5 | 64 |
| 9 | Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. <i>Journal of Affective Disorders</i> , 2004, 78, 201-208. | 4.1 | 54 |
| 10 | A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 885-893. | 3.0 | 53 |
| 11 | Relation of BMI to a dual-energy X-ray absorptiometry measure of fatness. <i>British Journal of Nutrition</i> , 1999, 82, 49-55. | 2.3 | 49 |
| 12 | Psychological distress in fibromyalgia patients: A role for catechol-O-methyl-transferase Val158met polymorphism. <i>Health Psychology</i> , 2012, 31, 242-249. | 1.6 | 42 |
| 13 | Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1668-1676. | 4.7 | 42 |
| 14 | A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients – A twelve month follow-up. <i>Journal of Neuroimmunology</i> , 2015, 285, 68-70. | 2.3 | 41 |
| 15 | Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440. | 3.0 | 40 |
| 16 | Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1358-1367. | 4.7 | 36 |
| 17 | A new therapeutic approach for type 1 diabetes: Rationale for GNBAC1, an anti-HERV-Env monoclonal antibody. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2075-2084. | 4.4 | 32 |
| 18 | Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing/remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 888-892. | 3.0 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>EBioMedicine</i> , 2016, 6, 190-198. | 6.1 | 30 |
| 20 | Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF. <i>Journal of Neuroimmunology</i> , 2019, 332, 224-232. | 2.3 | 29 |
| 21 | Novel therapeutic options for multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 91-104. | 3.1 | 22 |
| 22 | Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study. <i>MABs</i> , 2016, 8, 854-860. | 5.2 | 18 |
| 23 | Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e144. | 6.0 | 16 |
| 24 | Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 255-265. | 3.8 | 16 |
| 25 | A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis – Rationale and design. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 95-100. | 2.0 | 15 |
| 26 | The role of adaptive trial designs in drug development. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 727-736. | 3.1 | 14 |
| 27 | Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. <i>Journal of Psychopharmacology</i> , 2002, 16, 271-272. | 4.0 | 13 |
| 28 | Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review. <i>Drug Safety</i> , 2020, 43, 1287-1296. | 3.2 | 12 |
| 29 | Meta-analysis combining parallel and crossover trials with random effects. <i>Research Synthesis Methods</i> , 2017, 8, 263-274. | 8.7 | 10 |
| 30 | A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. <i>Clinical Therapeutics</i> , 2019, 41, 1737-1746. | 2.5 | 10 |
| 31 | Psychosocial Profile of Swiss Sexual Offenders. <i>Journal of Forensic Sciences</i> , 1998, 43, 755-759. | 1.6 | 10 |
| 32 | A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1111-1121. | 4.4 | 9 |
| 33 | Corrections to effect size variances for continuous outcomes of crossover clinical trials. <i>Statistics in Medicine</i> , 2018, 37, 320-323. | 1.6 | 8 |
| 34 | Meta-analysis combining parallel and crossover trials using generalised estimating equation method. <i>Research Synthesis Methods</i> , 2017, 8, 312-320. | 8.7 | 5 |
| 35 | GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the $\alpha 2$ subunit preferring GABA positive allosteric modulator, desmethylclobazam in healthy volunteers. <i>European Journal of Pain</i> , 2020, 24, 1094-1106. | 2.8 | 3 |
| 36 | Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?. <i>Journal of Neurology & Neurophysiology</i> , 2014, 05, . | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients. <i>Frontiers in Genetics</i> , 2021, 12, 816908. | 2.3 | 1 |